Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
4.350
+0.200 (4.82%)
At close: Oct 15, 2026, 4:00 PM EDT
4.420
+0.070 (1.61%)
After-hours: Oct 15, 2026, 7:47 PM EDT
Myriad Genetics Revenue
Myriad Genetics had revenue of $190.70M in the quarter ending June 30, 2026, a decrease of -10.51%. This brings the company's revenue in the last twelve months to $806.60M, down -3.16% year-over-year. In the year 2025, Myriad Genetics had annual revenue of $824.50M, down -1.56%. That makes Myriad Genetics the 8,637th largest company in the world by revenue and 1,937th in the United States.
Revenue (ttm)
$806.60M
Revenue Growth
-3.16%
P/S Ratio
0.52
Revenue / Employee
$298,741
Employees
2,700
Market Cap
416.08M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 824.50M | -13.10M | -1.56% |
| Dec 31, 2024 | 837.60M | 84.40M | 11.21% |
| Dec 31, 2023 | 753.20M | 74.80M | 11.03% |
| Dec 31, 2022 | 678.40M | -12.20M | -1.77% |
| Dec 31, 2021 | 690.60M | 52.00M | 8.14% |
| Jun 30, 2020 | 638.60M | -212.50M | -24.97% |
| Jun 30, 2019 | 851.10M | 107.40M | 14.44% |
| Jun 30, 2018 | 743.70M | 15.00M | 2.06% |
| Jun 30, 2017 | 728.70M | -11.80M | -1.59% |
| Jun 30, 2016 | 740.50M | 17.40M | 2.41% |
| Jun 30, 2015 | 723.10M | -55.10M | -7.08% |
| Jun 30, 2014 | 778.20M | 165.00M | 26.91% |
| Jun 30, 2013 | 613.20M | 117.20M | 23.63% |
| Jun 30, 2012 | 496.01M | 93.92M | 23.36% |
| Jun 30, 2011 | 402.08M | 39.44M | 10.87% |
| Jun 30, 2010 | 362.65M | 36.12M | 11.06% |
| Jun 30, 2009 | 326.53M | 103.67M | 46.52% |
| Jun 30, 2008 | 222.86M | 77.57M | 53.39% |
| Jun 30, 2007 | 145.29M | 31.01M | 27.13% |
| Jun 30, 2006 | 114.28M | 31.87M | 38.68% |
| Jun 30, 2005 | 82.41M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| OPKO Health | 587.90M |
| GeneDx Holdings | 454.43M |
| Castle Biosciences | 357.28M |
| Fulgent Genetics | 323.93M |
| Biodesix | 102.94M |
| Burning Rock Biotech | 73.70M |
| Exagen | 71.12M |
| Personalis | 69.67M |
MYGN News
- 6 hours ago - Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026 - GlobeNewsWire
- 2 days ago - Myriad Genetics price target raised to $4.50 from $4 at TD Cowen - TheFly
- 7 days ago - Sophia Genetics and Myriad Genetics collaborate in prostate cancer score tech - TheFly
- 7 days ago - Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology - GlobeNewsWire
- 7 days ago - SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology - PRNewsWire
- 13 days ago - Myriad Genetics price target raised to $8 from $4 at Craig-Hallum - TheFly
- 4 weeks ago - Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial - GlobeNewsWire
- 5 weeks ago - Myriad Genetics Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts